Jag Capital Management LLC Sells 72,305 Shares of Natera, Inc. (NASDAQ:NTRA)

Jag Capital Management LLC decreased its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 41.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 103,285 shares of the medical research company’s stock after selling 72,305 shares during the quarter. Natera accounts for about 2.3% of Jag Capital Management LLC’s investment portfolio, making the stock its 14th biggest position. Jag Capital Management LLC’s holdings in Natera were worth $16,350,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in NTRA. Blue Trust Inc. increased its holdings in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the period. Versant Capital Management Inc increased its holdings in shares of Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after purchasing an additional 166 shares during the period. Covestor Ltd increased its holdings in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the period. Principal Securities Inc. increased its holdings in shares of Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares during the period. Finally, True Wealth Design LLC acquired a new stake in shares of Natera during the 3rd quarter valued at about $57,000. Institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling

In related news, CEO Steven Leonard Chapman sold 78,553 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the sale, the chief executive officer now directly owns 267,629 shares of the company’s stock, valued at $44,150,756.13. The trade was a 22.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Michael Burkes Brophy sold 43,502 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $176.88, for a total transaction of $7,694,633.76. Following the completion of the sale, the chief financial officer now directly owns 70,629 shares of the company’s stock, valued at $12,492,857.52. The trade was a 38.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 208,299 shares of company stock valued at $34,948,265 over the last ninety days. Insiders own 7.60% of the company’s stock.

Natera Trading Down 8.0 %

Shares of NASDAQ NTRA opened at $143.11 on Tuesday. Natera, Inc. has a 1-year low of $83.13 and a 1-year high of $183.00. The company has a market cap of $18.89 billion, a PE ratio of -81.31 and a beta of 1.66. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The company has a 50-day moving average of $167.44 and a two-hundred day moving average of $147.35.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. As a group, equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on NTRA. Craig Hallum lifted their target price on shares of Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Piper Sandler lifted their target price on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, November 18th. Barclays began coverage on shares of Natera in a research report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 target price on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $180.00 target price on shares of Natera in a research report on Wednesday, February 26th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $172.69.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.